Nimotuzumab in the Treatment of Inoperable Esophageal Tumors of Epithelial Origin
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Oncology"
DOI: 10.1155/2022/4128946
Abstract: Background Nimotuzumab is a humanized monoclonal antibody that targets the epidermal growth factor receptor. It was approved in Cuba for the indication of inoperable malignant tumors of the esophagus of epithelial origin. The purpose of… read more here.
Keywords: inoperable esophageal; esophageal tumors; progression free; epithelial origin ... See more keywords